Premium
Immunotherapy for pancreatic ductal adenocarcinoma
Author(s) -
Carpenter Eileen,
Nelson Sarah,
Bednar Filip,
Cho Clifford,
Nathan Hari,
Sahai Vaibhav,
Magliano Marina Pasca,
Frankel Timothy L.
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26312
Subject(s) - medicine , immunotherapy , immune system , pancreatic ductal adenocarcinoma , pancreatic cancer , immune checkpoint , blockade , adenocarcinoma , cancer , oncology , targeted therapy , myeloid , pancreatic carcinoma , cancer research , immunology , receptor
Pancreatic ductal adenocarcinoma (PDAC) remains a lethal cancer with an urgent need for better medical therapies. Efforts have been made to investigate the efficacy of immunotherapy, particularly given the hallmarks of immune suppression and exhaustion in PDAC tumors. Here, we review the molecular components responsible for the immune‐privileged state in PDAC and provide an overview of the immunotherapeutic strategies for PDAC including vaccine therapy, checkpoint blockade, myeloid‐targeted therapy, and immune agonist therapy.